Comparison of different intravenous bisphosphonate regimens for Paget's disease of bone

Daniela Merlotti, Luigi Gennari, Giuseppe Martini, Fabrizio Valleggi, Vincenzo De Paola, Annalisa Avanzati, Ranuccio Nuti

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

This randomized study compared different intravenous bisphosphonates in PDB. Zoledronate was superior with respect to pamidronate in achieving biochemical remission, with therapeutic response maintained in most patients at 15 mo. Single neridronate and zoledronate infusion showed a similar efficacy in up to 90% of patients nonresponders to pamidronate. Introduction: Intravenous bisphosphonates represent a common therapy for Paget's disease of bone (PDB). However, there have been few head to head randomized trials comparing intravenous bisphosphonates. Materials and Methods: We performed a 15-mo, randomized study comparing different intravenous bisphosphonates in 90 subjects with active PDB. At baseline, patients were randomly assigned to receive pamidronate (30 mg, IV, for 2 consecutive days every 3 mo; n = 60) or zoledronate (4 mg, IV; n = 30). After 6 mo, nonresponders to pamidronate were crossed over to zoledronate or neridronate (100 mg, IV, for 2 consecutive days). The primary efficacy endpoint was therapeutic response at 6 mo, defined as normalization of alkaline phosphatase (ALP) or a reduction of at least 75 % in total ALP excess. Results: At 6 mo, 97% of patients receiving zoledronate had a therapeutic response compared with 45% of patients receiving pamidronate. Normalization of ALP was achieved in 93% of patients in the zoledronate group and in 35% of patients in the pamidronate group. ALP normalization was maintained in 79% and 65% of zoledronate-treated patients after 12 and 15 mo, respectively; loss of therapeutic response was observed in 2 of 30 (6%) at 12 and 15 mo. At 6 mo, 27 patients showing therapeutic response to pamidronate continued the treatment, whereas nonresponders were crossed-over to neridronate (n = 15) or zoledronate (n = 18). Among these subjects, 14 of 15 (93%) in the neridronate group and 17 of 18 (94%) in the zoledronate group achieved a therapeutic response. Similar normalization rates were observed between neridronate- (80%) and zoledronate- (83%) treated subjects. Normalization and therapeutic response were maintained at 9 mo from treatment (corresponding to 15 mo from the baseline visit) in either neridronate or zoledronate groups. Conclusions: Single neridronate and zoledronate infusion showed a similar efficacy in achieving biochemical remission in up to 90% of patients nonresponders to pamidronate. Therapeutic response to zoledronate seems to be maintained in most patients at 15 mo.

Original languageEnglish
Pages (from-to)1510-1517
Number of pages8
JournalJournal of Bone and Mineral Research
Volume22
Issue number10
DOIs
Publication statusPublished - Oct 2007

Fingerprint

zoledronic acid
pamidronate
Osteitis Deformans
Diphosphonates
Alkaline Phosphatase
Therapeutics

Keywords

  • Bisphosphonate
  • Neridronate
  • Paget's disease of bone
  • Treatment
  • Zoledronic acid

ASJC Scopus subject areas

  • Surgery

Cite this

Merlotti, D., Gennari, L., Martini, G., Valleggi, F., De Paola, V., Avanzati, A., & Nuti, R. (2007). Comparison of different intravenous bisphosphonate regimens for Paget's disease of bone. Journal of Bone and Mineral Research, 22(10), 1510-1517. https://doi.org/10.1359/jbmr.070704

Comparison of different intravenous bisphosphonate regimens for Paget's disease of bone. / Merlotti, Daniela; Gennari, Luigi; Martini, Giuseppe; Valleggi, Fabrizio; De Paola, Vincenzo; Avanzati, Annalisa; Nuti, Ranuccio.

In: Journal of Bone and Mineral Research, Vol. 22, No. 10, 10.2007, p. 1510-1517.

Research output: Contribution to journalArticle

Merlotti, D, Gennari, L, Martini, G, Valleggi, F, De Paola, V, Avanzati, A & Nuti, R 2007, 'Comparison of different intravenous bisphosphonate regimens for Paget's disease of bone', Journal of Bone and Mineral Research, vol. 22, no. 10, pp. 1510-1517. https://doi.org/10.1359/jbmr.070704
Merlotti D, Gennari L, Martini G, Valleggi F, De Paola V, Avanzati A et al. Comparison of different intravenous bisphosphonate regimens for Paget's disease of bone. Journal of Bone and Mineral Research. 2007 Oct;22(10):1510-1517. https://doi.org/10.1359/jbmr.070704
Merlotti, Daniela ; Gennari, Luigi ; Martini, Giuseppe ; Valleggi, Fabrizio ; De Paola, Vincenzo ; Avanzati, Annalisa ; Nuti, Ranuccio. / Comparison of different intravenous bisphosphonate regimens for Paget's disease of bone. In: Journal of Bone and Mineral Research. 2007 ; Vol. 22, No. 10. pp. 1510-1517.
@article{faa72030b3a749b49a189391eeea5773,
title = "Comparison of different intravenous bisphosphonate regimens for Paget's disease of bone",
abstract = "This randomized study compared different intravenous bisphosphonates in PDB. Zoledronate was superior with respect to pamidronate in achieving biochemical remission, with therapeutic response maintained in most patients at 15 mo. Single neridronate and zoledronate infusion showed a similar efficacy in up to 90{\%} of patients nonresponders to pamidronate. Introduction: Intravenous bisphosphonates represent a common therapy for Paget's disease of bone (PDB). However, there have been few head to head randomized trials comparing intravenous bisphosphonates. Materials and Methods: We performed a 15-mo, randomized study comparing different intravenous bisphosphonates in 90 subjects with active PDB. At baseline, patients were randomly assigned to receive pamidronate (30 mg, IV, for 2 consecutive days every 3 mo; n = 60) or zoledronate (4 mg, IV; n = 30). After 6 mo, nonresponders to pamidronate were crossed over to zoledronate or neridronate (100 mg, IV, for 2 consecutive days). The primary efficacy endpoint was therapeutic response at 6 mo, defined as normalization of alkaline phosphatase (ALP) or a reduction of at least 75 {\%} in total ALP excess. Results: At 6 mo, 97{\%} of patients receiving zoledronate had a therapeutic response compared with 45{\%} of patients receiving pamidronate. Normalization of ALP was achieved in 93{\%} of patients in the zoledronate group and in 35{\%} of patients in the pamidronate group. ALP normalization was maintained in 79{\%} and 65{\%} of zoledronate-treated patients after 12 and 15 mo, respectively; loss of therapeutic response was observed in 2 of 30 (6{\%}) at 12 and 15 mo. At 6 mo, 27 patients showing therapeutic response to pamidronate continued the treatment, whereas nonresponders were crossed-over to neridronate (n = 15) or zoledronate (n = 18). Among these subjects, 14 of 15 (93{\%}) in the neridronate group and 17 of 18 (94{\%}) in the zoledronate group achieved a therapeutic response. Similar normalization rates were observed between neridronate- (80{\%}) and zoledronate- (83{\%}) treated subjects. Normalization and therapeutic response were maintained at 9 mo from treatment (corresponding to 15 mo from the baseline visit) in either neridronate or zoledronate groups. Conclusions: Single neridronate and zoledronate infusion showed a similar efficacy in achieving biochemical remission in up to 90{\%} of patients nonresponders to pamidronate. Therapeutic response to zoledronate seems to be maintained in most patients at 15 mo.",
keywords = "Bisphosphonate, Neridronate, Paget's disease of bone, Treatment, Zoledronic acid",
author = "Daniela Merlotti and Luigi Gennari and Giuseppe Martini and Fabrizio Valleggi and {De Paola}, Vincenzo and Annalisa Avanzati and Ranuccio Nuti",
year = "2007",
month = "10",
doi = "10.1359/jbmr.070704",
language = "English",
volume = "22",
pages = "1510--1517",
journal = "Journal of Bone and Mineral Research",
issn = "0884-0431",
publisher = "Wiley-Blackwell",
number = "10",

}

TY - JOUR

T1 - Comparison of different intravenous bisphosphonate regimens for Paget's disease of bone

AU - Merlotti, Daniela

AU - Gennari, Luigi

AU - Martini, Giuseppe

AU - Valleggi, Fabrizio

AU - De Paola, Vincenzo

AU - Avanzati, Annalisa

AU - Nuti, Ranuccio

PY - 2007/10

Y1 - 2007/10

N2 - This randomized study compared different intravenous bisphosphonates in PDB. Zoledronate was superior with respect to pamidronate in achieving biochemical remission, with therapeutic response maintained in most patients at 15 mo. Single neridronate and zoledronate infusion showed a similar efficacy in up to 90% of patients nonresponders to pamidronate. Introduction: Intravenous bisphosphonates represent a common therapy for Paget's disease of bone (PDB). However, there have been few head to head randomized trials comparing intravenous bisphosphonates. Materials and Methods: We performed a 15-mo, randomized study comparing different intravenous bisphosphonates in 90 subjects with active PDB. At baseline, patients were randomly assigned to receive pamidronate (30 mg, IV, for 2 consecutive days every 3 mo; n = 60) or zoledronate (4 mg, IV; n = 30). After 6 mo, nonresponders to pamidronate were crossed over to zoledronate or neridronate (100 mg, IV, for 2 consecutive days). The primary efficacy endpoint was therapeutic response at 6 mo, defined as normalization of alkaline phosphatase (ALP) or a reduction of at least 75 % in total ALP excess. Results: At 6 mo, 97% of patients receiving zoledronate had a therapeutic response compared with 45% of patients receiving pamidronate. Normalization of ALP was achieved in 93% of patients in the zoledronate group and in 35% of patients in the pamidronate group. ALP normalization was maintained in 79% and 65% of zoledronate-treated patients after 12 and 15 mo, respectively; loss of therapeutic response was observed in 2 of 30 (6%) at 12 and 15 mo. At 6 mo, 27 patients showing therapeutic response to pamidronate continued the treatment, whereas nonresponders were crossed-over to neridronate (n = 15) or zoledronate (n = 18). Among these subjects, 14 of 15 (93%) in the neridronate group and 17 of 18 (94%) in the zoledronate group achieved a therapeutic response. Similar normalization rates were observed between neridronate- (80%) and zoledronate- (83%) treated subjects. Normalization and therapeutic response were maintained at 9 mo from treatment (corresponding to 15 mo from the baseline visit) in either neridronate or zoledronate groups. Conclusions: Single neridronate and zoledronate infusion showed a similar efficacy in achieving biochemical remission in up to 90% of patients nonresponders to pamidronate. Therapeutic response to zoledronate seems to be maintained in most patients at 15 mo.

AB - This randomized study compared different intravenous bisphosphonates in PDB. Zoledronate was superior with respect to pamidronate in achieving biochemical remission, with therapeutic response maintained in most patients at 15 mo. Single neridronate and zoledronate infusion showed a similar efficacy in up to 90% of patients nonresponders to pamidronate. Introduction: Intravenous bisphosphonates represent a common therapy for Paget's disease of bone (PDB). However, there have been few head to head randomized trials comparing intravenous bisphosphonates. Materials and Methods: We performed a 15-mo, randomized study comparing different intravenous bisphosphonates in 90 subjects with active PDB. At baseline, patients were randomly assigned to receive pamidronate (30 mg, IV, for 2 consecutive days every 3 mo; n = 60) or zoledronate (4 mg, IV; n = 30). After 6 mo, nonresponders to pamidronate were crossed over to zoledronate or neridronate (100 mg, IV, for 2 consecutive days). The primary efficacy endpoint was therapeutic response at 6 mo, defined as normalization of alkaline phosphatase (ALP) or a reduction of at least 75 % in total ALP excess. Results: At 6 mo, 97% of patients receiving zoledronate had a therapeutic response compared with 45% of patients receiving pamidronate. Normalization of ALP was achieved in 93% of patients in the zoledronate group and in 35% of patients in the pamidronate group. ALP normalization was maintained in 79% and 65% of zoledronate-treated patients after 12 and 15 mo, respectively; loss of therapeutic response was observed in 2 of 30 (6%) at 12 and 15 mo. At 6 mo, 27 patients showing therapeutic response to pamidronate continued the treatment, whereas nonresponders were crossed-over to neridronate (n = 15) or zoledronate (n = 18). Among these subjects, 14 of 15 (93%) in the neridronate group and 17 of 18 (94%) in the zoledronate group achieved a therapeutic response. Similar normalization rates were observed between neridronate- (80%) and zoledronate- (83%) treated subjects. Normalization and therapeutic response were maintained at 9 mo from treatment (corresponding to 15 mo from the baseline visit) in either neridronate or zoledronate groups. Conclusions: Single neridronate and zoledronate infusion showed a similar efficacy in achieving biochemical remission in up to 90% of patients nonresponders to pamidronate. Therapeutic response to zoledronate seems to be maintained in most patients at 15 mo.

KW - Bisphosphonate

KW - Neridronate

KW - Paget's disease of bone

KW - Treatment

KW - Zoledronic acid

UR - http://www.scopus.com/inward/record.url?scp=38449091517&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38449091517&partnerID=8YFLogxK

U2 - 10.1359/jbmr.070704

DO - 10.1359/jbmr.070704

M3 - Article

C2 - 17605632

AN - SCOPUS:38449091517

VL - 22

SP - 1510

EP - 1517

JO - Journal of Bone and Mineral Research

JF - Journal of Bone and Mineral Research

SN - 0884-0431

IS - 10

ER -